Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children
Key facts
- Who runs it
- Singapore National Eye Centre
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 202 people, planned
- Started
- 2 Jan 2025
- Expected to end
- 2 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EYE001
- Record updated
- 4 December 2024
Who can take part
- Age
- 6 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Subjects must meet all the criteria listed to participate in the study:
- All ethnicities
- Age between 6 and 15 years
- Refraction -0.50D till - 7.00D and astigmatism ≤ 3.00D
- Anisometropia ≤ 3.00D
- Best corrected monocular distance high contrast VA ≤ 0.10 logMAR
- Normal Binocular vision (fusion and stereopsis)
Who cannot take part
- Previous use of myopia management treatment (spectacles, atropine, CLs)
- Neurological disorders
- Subject is allergic to cycloplegic eye drops
- All subjects meeting any of the exclusion criteria at baseline will be excluded from participation:
- Ocular and systemic abnormalities
- Children who do not cooperate
- Binocular vision anomalies (strabismus, suppression)
- Premature infants
- Children who do not wear their glasses correctly for intermediate and near vision activities
- Children who do not meet the inclusion criteria
- No informed consent given by parents of child for participation in the clinical study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 15 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study aims to evaluate the non-inferiority of the photochromic DIMS spectacles lenses performance (PDIMS) compared to clear DIMS spectacles lenses (DIMS) in myopia management.
The 2 groups in the trial
- Children on clear DIMS lensesExisting treatment, for comparison
202 children will be recruited at 6 institutions following the rules of inclusion and exclusion criteria. Based on a randomization process defined from the study coordinator, children will be allocated to 2 groups: DIMS and PDIMS. The study will be single blinded, meaning that the investigators are not aware of which type of treatment will be associated with which subjects. Subjects cannot be blinded due to the darkening of PDIMS that allows recognition on the type of lens.
Treatment: EYE001
- Children on photochromic DIMS lensesExisting treatment, for comparison
202 children will be recruited at 6 institutions following the rules of inclusion and exclusion criteria. Based on a randomization process defined from the study coordinator, children will be allocated to 2 groups: DIMS and PDIMS. The study will be single blinded, meaning that the investigators are not aware of which type of treatment will be associated with which subjects. Subjects cannot be blinded due to the darkening of PDIMS that allows recognition on the type of lens.
Treatment: EYE001
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children.
- Criteria questions
- Built from NCT06717035, who can take part
- Record updated
- 4 December 2024